{"SLR NAME":"The effects of ACEIs/ARBs on mortality in COVID-19 infected patients: a meta-analysis and systematic review","References":[{"title1":"Angiotensin?converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID?19","References":[{"title2":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","References":[{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20inhibitors%20in%20patients%20with%20Covid-19"}]},{"title2":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","References":[{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"}]},{"title2":"Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19","References":[]},{"title2":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","References":[{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"},{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"},{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"},{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"},{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"},{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"},{"title3":"Can%20angiotensin%20receptor-blocking%20drugs%20perhaps%20be%20harmful%20in%20the%20COVID-19%20pandemic?"}]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"}]},{"title2":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","References":[]},{"title2":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection","References":[{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"},{"title3":"Coronavirus%20disease%202019%20(COVID-19)%20and%20cardiovascular%20disease:%20a%20viewpoint%20on%20the%20potential%20influence%20of%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20on%20onset%20and%20severity%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection"}]},{"title2":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy","References":[]},{"title2":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","References":[]},{"title2":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","References":[]},{"title2":"Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study","References":[]},{"title2":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","References":[{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"}]},{"title2":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?","References":[{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"},{"title3":"Coronavirus%20disease%202019%20(COVID-19):%20do%20angiotensin-converting%20enzyme%20inhibitors/angiotensin%20receptor%20blockers%20have%20a%20biphasic%20effect?"}]},{"title2":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence?","References":[{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers.%20What%20is%20the%20evidence?"}]},{"title2":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","References":[]},{"title2":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","References":[{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"}]},{"title2":"Hypertension and COVID-19","References":[{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"},{"title3":"Hypertension%20and%20COVID-19"}]},{"title2":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","References":[]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","References":[]},{"title2":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","References":[]},{"title2":"The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function","References":[]},{"title2":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats","References":[]},{"title2":"Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers","References":[]},{"title2":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","References":[{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"},{"title3":"Renin-angiotensin-aldosterone%20system%20blockers%20and%20the%20risk%20of%20Covid-19"}]},{"title2":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","References":[{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"},{"title3":"Use%20of%20renin-angiotensin-aldosterone%20system%20inhibitors%20and%20risk%20of%20COVID-19%20requiring%20admission%20to%20hospital:%20a%20case-population%20study"}]},{"title2":"  . Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers [cited 2020 Mar 13]. Available from URL: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang ","References":[]},{"title2":"The national early warning score 2 (NEWS2)","References":[{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"},{"title3":"The%20national%20early%20warning%20score%202%20(NEWS2)"}]},{"title2":"National early warning score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS","References":[]},{"title2":"Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020","References":[]},{"title2":"An interactive web-based dashboard to track COVID-19 in real time","References":[{"title3":"An%20interactive%20web-based%20dashboard%20to%20track%20COVID-19%20in%20real%20time"},{"title3":"An%20interactive%20web-based%20dashboard%20to%20track%20COVID-19%20in%20real%20time"},{"title3":"An%20interactive%20web-based%20dashboard%20to%20track%20COVID-19%20in%20real%20time"}]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"}]},{"title2":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","References":[]},{"title2":"Comparative effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD","References":[{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"},{"title3":"Comparative%20effects%20of%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20the%20risk%20of%20pneumonia%20and%20severe%20exacerbations%20in%20patients%20with%20COPD"}]},{"title2":"Severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis","References":[{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"},{"title3":"Severity%20and%20mortality%20associated%20with%20COPD%20and%20smoking%20in%20patients%20with%20COVID-19:%20a%20rapid%20systematic%20review%20and%20meta-analysis"}]},{"title2":"Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension","References":[]},{"title2":"Clinical characteristics and prognostic factors in COVID-19 patients aged &gt;=80 years","References":[{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"},{"title3":"Clinical%20characteristics%20and%20prognostic%20factors%20in%20COVID-19%20patients%20aged%20&gt;=80%20years"}]},{"title2":"Recommendations for the admission of patients with COVID-19 to intensive care and intermediate care units (ICUs and IMCUs)","References":[]},{"title2":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","References":[]},{"title2":"Rapid response systems","References":[{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"},{"title3":"Rapid%20response%20systems"}]},{"title2":"In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival","References":[]},{"title2":"Prognostic value of early warning scores in the emergency department (ED) and acute medical unit (AMU): a narrative review","References":[]},{"title2":"National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study","References":[{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"},{"title3":"National%20Early%20Warning%20Score%202%20(NEWS2)%20on%20admission%20predicts%20severe%20disease%20and%20in-hospital%20mortality%20from%20Covid-19%20-%20a%20prospective%20cohort%20study"}]}]},{"title1":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","References":[{"title2":"World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report - 45. Geneva, Switzerland: World Health Organization; March 20, 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","References":[{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China."}]},{"title2":"Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. [Epub ahead of print].","References":[]},{"title2":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.","References":[{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."},{"title3":"Prevalence%20and%20impact%20of%20cardiovascular%20metabolic%20diseases%20on%20COVID-19%20in%20China."}]},{"title2":"Structure analysis of the receptor binding of 2019-nCoV.","References":[{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."},{"title3":"Structure%20analysis%20of%20the%20receptor%20binding%20of%202019-nCoV."}]},{"title2":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.","References":[{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission."}]},{"title2":"Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system.","References":[]},{"title2":"ACE2 of the heart: From angiotensin I to angiotensin (1-7).","References":[]},{"title2":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.","References":[]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.","References":[]},{"title2":"Renin Angiotensin system-modifying therapies are associated with improved pulmonary health.","References":[{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."},{"title3":"Renin%20Angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health."}]},{"title2":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.","References":[]},{"title2":"Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA statement addresses concerns re:using RAAS antagonists in COVID-19. March 17, 2020. Available online: https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp","References":[]},{"title2":"ESH Statement on COVID-19: Statement of the European Society of Hypertension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19. March 12, 2020. Available online: https://www.eshonline.org/","References":[]},{"title2":"General Office of National Health Commission. Diagnosis and treatment of novel coronavirus pneumonia (5th edition, 2020) 2020:1-12.","References":[]},{"title2":"Kenneth Schulz, David Grimes. Essential Concepts in Clinical Research - 2nd Edition Essential Concepts in Clinical Research: Randomised Controlled Trials and Observational Epidemiology (2nd ed.). Elsevier, 24th September 2018, ISBN: 9780702073946.","References":[]},{"title2":"R. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension.","References":[]},{"title2":"Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association.","References":[]},{"title2":"NT-pro BNP and plasma-soluble ST2 as promising biomarkers for hypertension, hypertensive heart disease and heart failure in sub-Saharan Africa.","References":[{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."},{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."},{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."},{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."},{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."},{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."},{"title3":"NT-pro%20BNP%20and%20plasma-soluble%20ST2%20as%20promising%20biomarkers%20for%20hypertension,%20hypertensive%20heart%20disease%20and%20heart%20failure%20in%20sub-Saharan%20Africa."}]},{"title2":"Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes.","References":[]},{"title2":"Renin-angiotensin system inhibitors and troponin elevation in spinal surgery.","References":[]},{"title2":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.","References":[]},{"title2":"Olmesartan attenuates pressure-overload- or post-infarction-induced cardiac remodeling in mice.","References":[{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."},{"title3":"Olmesartan%20attenuates%20pressure-overload-%20or%20post-infarction-induced%20cardiac%20remodeling%20in%20mice."}]},{"title2":"Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.","References":[]},{"title2":"ARB may be superior to ACEI on treatment of Marfan's syndrome by blocking TGF-beta mediated activation of ERK.","References":[]}]},{"title1":"Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome","References":[{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"}]},{"title2":"A novel coronavirus from patients with pneumonia in China, 2019","References":[{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"},{"title3":"A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China,%202019"}]},{"title2":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","References":[{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"},{"title3":"Epidemiological%20and%20clinical%20characteristics%20of%2099%20cases%20of%202019%20novel%20coronavirus%20pneumonia%20in%20Wuhan,%20China:%20a%20descriptive%20study"}]},{"title2":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","References":[{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"},{"title3":"Cardiovascular%20implications%20of%20fatal%20outcomes%20of%20patients%20with%20coronavirus%20disease%202019%20(COVID-19)"}]},{"title2":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","References":[]},{"title2":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","References":[]},{"title2":"Upregulation of angiotensin converting enzyme 2 by shear stress reduced inflammation and proliferation in vascular endothelial cells","References":[]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","References":[]},{"title2":"Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts","References":[{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"},{"title3":"Cell%20type-specific%20expression%20of%20the%20putative%20SARS-CoV-2%20receptor%20ACE2%20in%20human%20hearts"}]},{"title2":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","References":[{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"},{"title3":"SARS-CoV-2%20cell%20entry%20depends%20on%20ACE2%20and%20TMPRSS2%20and%20is%20blocked%20by%20a%20clinically%20proven%20protease%20inhibitor"}]},{"title2":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","References":[{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"},{"title3":"Are%20patients%20with%20hypertension%20and%20diabetes%20mellitus%20at%20increased%20risk%20for%20COVID-19%20infection?"}]},{"title2":"Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity","References":[{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"},{"title3":"Hypertension%20prevalence%20in%20human%20coronavirus%20disease:%20the%20role%20of%20ACE%20system%20in%20infection%20spread%20and%20severity"}]},{"title2":"Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension","References":[{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"},{"title3":"Antihypertensive%20treatment%20with%20ACEI/ARB%20of%20patients%20with%20COVID-19%20complicated%20by%20hypertension"}]},{"title2":"COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease","References":[{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"},{"title3":"COVID-19%20and%20heart%20failure:%20from%20infection%20to%20inflammation%20and%20angiotensin%20II%20stimulation.%20Searching%20for%20evidence%20from%20a%20new%20disease"}]},{"title2":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","References":[{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"},{"title3":"Renin-angiotensin%20system%20blockers%20and%20the%20COVID-19%20pandemic:%20at%20present%20there%20is%20no%20evidence%20to%20abandon%20renin-angiotensin%20system%20blockers"}]},{"title2":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","References":[{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"},{"title3":"Potential%20harmful%20effects%20of%20discontinuing%20ACE-inhibitors%20and%20ARBs%20in%20COVID-19%20patients"}]},{"title2":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","References":[{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"},{"title3":"Risks%20of%20ACE%20inhibitor%20and%20ARB%20usage%20in%20COVID-19:%20evaluating%20the%20evidence"}]},{"title2":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19","References":[]},{"title2":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","References":[]},{"title2":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","References":[]},{"title2":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","References":[{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"},{"title3":"Renin-angiotensin%20system%20inhibitors%20improve%20the%20clinical%20outcomes%20of%20COVID-19%20patients%20with%20hypertension"}]},{"title2":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","References":[]},{"title2":"Renin-angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A statement of activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension","References":[{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"},{"title3":"Renin-angiotensin%20system%20inhibition%20in%20cardiovascular%20patients%20at%20the%20time%20of%20COVID19:%20much%20ado%20for%20nothing?%20A%20statement%20of%20activity%20from%20the%20Directors%20of%20the%20Board%20and%20the%20Scientific%20Directors%20of%20the%20Italian%20Society%20of%20Hypertension"}]},{"title2":"Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers","References":[{"title3":"Comorbidities%20in%20COVID-19:%20outcomes%20in%20hypertensive%20cohort%20and%20controversies%20with%20renin%20angiotensin%20system%20blockers"},{"title3":"Comorbidities%20in%20COVID-19:%20outcomes%20in%20hypertensive%20cohort%20and%20controversies%20with%20renin%20angiotensin%20system%20blockers"},{"title3":"Comorbidities%20in%20COVID-19:%20outcomes%20in%20hypertensive%20cohort%20and%20controversies%20with%20renin%20angiotensin%20system%20blockers"},{"title3":"Comorbidities%20in%20COVID-19:%20outcomes%20in%20hypertensive%20cohort%20and%20controversies%20with%20renin%20angiotensin%20system%20blockers"}]},{"title2":"Cohort of four thousand four hundred four persons under investigation for COVID-19 in a New York hospital and predictors of ICU care and ventilation","References":[{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"},{"title3":"Cohort%20of%20four%20thousand%20four%20hundred%20four%20persons%20under%20investigation%20for%20COVID-19%20in%20a%20New%20York%20hospital%20and%20predictors%20of%20ICU%20care%20and%20ventilation"}]},{"title2":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","References":[]},{"title2":"Cardiac remodelling and RAS inhibition","References":[{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"},{"title3":"Cardiac%20remodelling%20and%20RAS%20inhibition"}]},{"title2":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","References":[]},{"title2":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","References":[]},{"title2":"Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade","References":[]},{"title2":"Inside the heart of COVID-19","References":[]},{"title2":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19","References":[{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"},{"title3":"Interactions%20of%20coronaviruses%20with%20ACE2,%20angiotensin%20II,%20and%20RAS%20inhibitors-lessons%20from%20available%20evidence%20and%20insights%20into%20COVID-19"}]}]},{"title1":"Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID?19 patients with hypertension in Wuhan: A hospital?based retrospective cohort study","References":[{"title2":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China","References":[{"title3":"The%20epidemiological%20characteristics%20of%20an%20outbreak%20of%202019%20novel%20coronavirus%20diseases%20(COVID-19)%20in%20China"}]},{"title2":"Is there an association between COVID-19 mortality and the renin-angiotensin system:a call for epidemiologic investigations","References":[{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"},{"title3":"Is%20there%20an%20association%20between%20COVID-19%20mortality%20and%20the%20renin-angiotensin%20system:a%20call%20for%20epidemiologic%20investigations"}]},{"title2":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","References":[{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"},{"title3":"Evolution%20of%20the%20novel%20coronavirus%20from%20the%20ongoing%20Wuhan%20outbreak%20and%20modeling%20of%20its%20spike%20protein%20for%20risk%20of%20human%20transmission"}]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","References":[]},{"title2":"Application status of antihypertensive drugs in patients with hypertension in southwest China","References":[]},{"title2":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","References":[]},{"title2":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice","References":[]},{"title2":"A language and environment for statistical computing Published online","References":[]},{"title2":"RStudio: integrated development for R","References":[]},{"title2":"Developing practical recommendations for the use of propensity scores: discussion of 'A critical appraisal of propensity score matching in the medical literature between 1996 and 2003' by Peter Austin, Statistics in Medicine","References":[]},{"title2":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","References":[]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"}]},{"title2":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","References":[{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"},{"title3":"SARS-CoV2:%20should%20inhibitors%20of%20the%20renin-angiotensin%20system%20be%20withdrawn%20in%20patients%20with%20COVID-19?"}]},{"title2":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension","References":[]},{"title2":"Renin angiotensin system-modifying therapies are associated with improved pulmonary health","References":[{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"},{"title3":"Renin%20angiotensin%20system-modifying%20therapies%20are%20associated%20with%20improved%20pulmonary%20health"}]},{"title2":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","References":[]},{"title2":"The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: a genetic association study in Brazilian patients","References":[{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"},{"title3":"The%20combination%20of%20ACE%20I/D%20and%20ACE2%20G8790A%20polymorphisms%20revels%20susceptibility%20to%20hypertension:%20a%20genetic%20association%20study%20in%20Brazilian%20patients"}]},{"title2":"ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus","References":[{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"},{"title3":"ACE2%20polymorphisms%20associated%20with%20cardiovascular%20risk%20in%20Uygurs%20with%20type%202%20diabetes%20mellitus"}]},{"title2":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","References":[]},{"title2":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","References":[]},{"title2":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","References":[{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"COVID-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"}]}]},{"title1":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","References":[{"title2":"Characteristics of and important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72 314 cases from the Chinese Center for disease control and Prevention","References":[]},{"title2":"Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia","References":[]},{"title2":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","References":[]},{"title2":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","References":[{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"},{"title3":"A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20(ACE2)%20in%20SARS%20coronavirus-induced%20lung%20injury"}]},{"title2":"Recent Update of renin-angiotensin-aldosterone","References":[{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"},{"title3":"Recent%20Update%20of%20renin-angiotensin-aldosterone"}]},{"title2":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury","References":[{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"},{"title3":"Angiotensin-converting%20enzyme%202%20(ACE2)%20mediates%20influenza%20H7N9%20virus-induced%20acute%20lung%20injury"}]},{"title2":"Effect of renin-angiotensin-aldosterone system inhibitors on short-Term mortality After sepsis: a population-based aohort study","References":[]},{"title2":"Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA","References":[]},{"title2":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway","References":[]},{"title2":"Beta Blocker and angiotensin-converting enzyme Inhibitor therapy Is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure","References":[]}]}]}